contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


attana-features-in-pharma-publications-with-avatm-as-a-leading-edge-solution-for-improved-sars-cov-2-testing-and-immunity-profiling

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Attana conducts research and development of pharmaceuticals. The company specializes in biological interaction characterization, which is used for analysis in the development of new drugs. The company's patented solutions are used in the study of binding properties and macrostructures in cells, proteins, viruses and bacteria. Operations are primarily in the Nordic region and Europe. The company was founded in 2002 and is headquartered in Stockholm.

Cut your losses quickly is a pretty good saying for companies like these.

This multibagger seems to have multibagged in the other direction, meaning only 1/20th of the value is left.

Got a small pile souring at the bottom of my portfolio and I’m not really that excited to participate in the offering. I have to admit I haven’t followed the company’s activities at all lately.

A share issue is incoming. I’m wondering if I should finally realize these -95% losses or continue to fund this sinking ship. Is anyone else still on board?

Börskollen              Kvartalsrapport för perioden 1 januari - 31 mars 2022 i Attana AB    Pressmeddelande i aktien Attana. Kvartalsrapport för perioden 1 januari - 31 mars 2022 i Attana AB.                             Financial overview (not audited by the company’s auditor):  Net sales SEK 3.1 (1.1) million Other operating income SEK 0.0 (0.0) million Operating profit SEK -2.1 (-3.4) million Profit after financial items SEK -2.1 (-3.5) million Profit after tax SEK -2.1 (-3.5) million Earnings per share - SEK 0.0102 (-0.0166)

Hyvä huomio, tuo ei tullut itsellä mieleen.

Olisiko IDL Biotechillä ollut tämän puolen osaamista? Sehän on nyt osa Arocelliä.

Attana

Recently, an article about Attana's first non-clinical in vitro diagnostic (IVD) device, Attana Virus Analytics - AVA™, was published in IBI (International Biopharmaceutical Industry). The article...

Recently, an article about Attana's first non-clinical in vitro diagnostic (IVD) device, Attana Virus Analytics - AVA™, was published in IBI (International Biopharmaceutical Industry). The article explains how AVA could help provide invaluable insights when assessing patient immunity for SARS-CoV-2.A brief summary of the article:The Challenge of Assessing SARS-CoV-2 Immunity One of the main challenges with SARS-CoV-2 is assessing patient immunity. Conventional testing methods focuse on the binary presence of virus-specific antibodies (e.g. IgA, IgM and IgG). However, SARS-CoV-2 immunity assessments requires a more nuanced analysis of the immune response, since a significant number of SARS-CoV-2 positive individuals have not developed any discernable antibody counts post-infection.  A Solution for Improved SARS-CoV-2 Immunity Assessing Attana Virus Analytics - AVA™ is a generic IVD device for non-clinical laboratory use, consisting of Attana's proprietary third-generation biosensor, various assays, and reagents. This technology enables AVA™ to take a broader approach when assessing immunity compared with the most prevalent virus diagnostics tools that are traditional based on ELSIA assays. By comparing an individual's immune responses in a series of tests, a full patient immunity profile can be established and manifested. The AVA™ platform could therefore provide invaluable insights on an individual patient level, as well as the most suitable vaccination programmes based on the population's immunity.Nest steps for AVA™ platform Although Attana recently entered the IVD market, our biosensor instruments have been used by Big Pharma, biotech companies, and academia for over 18 years and been highlighted in over 130 peer-reviewed publications. Attana have recently initiated a regulatory approval process for the AVA™ platform and will continue to engage in cross-disciplinary development of a point-of-care IVD device with AI-enabled automated analytic capabilities.    Read the full article here (<a href="https://issuu.com/mark123/docs/2020-covid-supplement-2-web_compres_0adc0150a61177/18">https://issuu.com/mark123/docs/2020-covid-supplement-2-web_compres_0adc0150a61177/18</a>).